Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer - Wikidata - wikimedia - TriplyDB

Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer

Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer

http://www.wikidata.org/entity/Q30497364

about

Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention Multivalent nanoparticle networks enable point-of-care detection of human phospholipase-A2 in serum.Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.Inhibitory effect of platinum and ruthenium bipyridyl complexes on porcine pancreatic phospholipase A2.Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules.Serum levels of arachidonic acid metabolites change during prostate cancer progression.Interactions of platinum and ruthenium coordination complexes with pancreatic phospholipase A(2) and phospholipids investigated by MALDI TOF mass spectrometry.A dangerous liaison: Leptin and sPLA2-IIA join forces to induce proliferation and migration of astrocytoma cells Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo.Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells.The role of phosphatidylcholine and choline metabolites to cell proliferation and survival.Role of the phospholipase A2 receptor in liposome drug delivery in prostate cancer cells.Phorbol ester stimulates ethanolamine release from the metastatic basal prostate cancer cell line PC3 but not from prostate epithelial cell lines LNCaP and P4E6.Serum amyloid A, phospholipase A₂-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases.Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer Platelet microparticle-mediated transfer of miR-939 to epithelial ovarian cancer cells promotes epithelial to mesenchymal transition.Secreted Phospholipase A2 Type IIA (sPLA2-IIA) Activates Integrins in an Allosteric Manner.sPLA2 -IIA Overexpression in Mice Epidermis Depletes Hair Follicle Stem Cells and Induces Differentiation Mediated Through Enhanced JNK/c-Jun Activation.

P2860

Q26997377-00B7BD05-FC4B-40BA-B510-5E165EA54EF7 Q33609955-8C39E76F-78E1-4647-9C9E-479804832EDF Q34000586-61BC7F46-1BA6-487B-ADDF-5E84ECE97300 Q34016733-37895835-D762-43A2-98EB-45C031722F8D Q34094060-FFDFE2E9-1B32-4055-A8A3-5651B798B061 Q34398467-1DDF1C1D-9FCC-435C-B365-D8BB17A99907 Q35045281-3E2BCFEF-EF08-4D32-BD38-862140318A6D Q36294159-87E66166-4A63-44DA-83F8-FA544E0CA358 Q37362770-4177626D-BC3E-4653-8E55-0EA219F4646C Q37374864-DF9B2A36-4CE8-41AD-9BC5-A92D5570DC92 Q38076754-70920C10-EC62-4723-90D0-D21484524DAA Q38959672-7D2AF63E-F6E5-4DFB-B30F-8A003C369BCE Q38964675-E66B922E-2B5F-4D75-AAD7-EFAF902B9941 Q39092660-BC68ABC6-4353-4CEF-9E12-6F4A7106EDE0 Q39435549-B57C0BB2-3557-43B1-9724-3F2BC9AB557E Q47117429-8A6DD0F9-CC41-46F0-B741-66B464F82E7C Q51316539-6E3E96DF-963C-4499-9893-768FBD4698D2 Q51703796-19298F5F-214B-4E87-B29D-77BB91040FFC

P2860

Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer

http://www.wikidata.org/entity/Q30497364

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Secretory phospholipase A2-IIa ...... biomarker for prostate cancer

@ast

Secretory phospholipase A2-IIa ...... biomarker for prostate cancer

@en

type

label

Secretory phospholipase A2-IIa ...... biomarker for prostate cancer

@ast

Secretory phospholipase A2-IIa ...... biomarker for prostate cancer

@en

prefLabel

Secretory phospholipase A2-IIa ...... biomarker for prostate cancer

@ast

Secretory phospholipase A2-IIa ...... biomarker for prostate cancer

@en

P1433

Q30497364-66814E2F-5925-4C07-A3DE-CEA8103B73A0

P1476

Q30497364-08479F90-E2EC-4057-8E1D-3438CDDE9DC3

P2093

Q30497364-17994BC4-C3CD-4900-ABAE-BF6A6E7596C4

Q30497364-2D12F141-8336-47F3-8A33-074904C89B5D

Q30497364-33C43DE0-173B-42DF-99A2-6D9B017FD0CC

Q30497364-3F1B0376-5E0B-4059-8B21-A6591C7F19BE

Q30497364-7FE418EE-C015-44D6-B242-ECDBD0FD665F

Q30497364-B93CFFC8-084A-42D0-942A-13BCE69C8AEA

Q30497364-BE53587D-CC07-4F54-95CC-1EF23134A6B6

Q30497364-C3FCF614-9494-4638-AA6E-BB8B63484F58

Q30497364-D3948413-6738-4CFB-B89F-1F7936F5B5F9

Q30497364-E5A9A9E0-E0FD-4231-A561-26EE82B93DCD

P2860

Q30497364-038A27EF-BDC7-4AC2-BFD4-3B257CAA889B

Q30497364-04B94595-912A-46F0-A3D6-1673E3C593C3

Q30497364-062BAF25-2B46-4D48-BEFE-F5D2A700B273

Q30497364-0F59A87E-C4B5-4DD2-981E-DA0A971B548E

Q30497364-172C0D37-653B-48A9-8E62-E82B50899B2D

Q30497364-19251B53-262E-41A9-8791-D66FCCC3B291

Q30497364-1FB32823-A7A7-4CB1-A7F3-8FAD321E4636

Q30497364-20C9C279-CDA9-4583-88A9-9005BBA5B04A

Q30497364-230721A1-8C76-4997-A610-57313EE87D8E

Q30497364-27186356-835A-4C2D-8912-211F3359C57B

P304

Q30497364-CB6928CA-1EE6-4EBE-9DD0-6E811EAAD8C9

P31

Q30497364-88BD7EE9-9F53-47A6-8792-6CC68274EF52

P356

Q30497364-503155D3-E2A8-4C6C-AF20-01C1E01A0802

P407

Q30497364-4385565B-5B94-40E3-AF70-34EBEDC62990

P433

Q30497364-DF159B7E-4B26-44E9-B73B-FAA9C8BD2D57

P478

Q30497364-401F77E7-0B39-4C1E-8074-19966C5FDFCB

P577

Q30497364-5D439318-A207-45C8-BD7D-166DC559FD3D

P5875

Q30497364-18F8B234-67C7-4E84-9DC0-72716C6F5DA6

P698

Q30497364-D1114FAD-6A72-4540-92C5-15525EA8F58D

P921

Q30497364-D808850B-3B56-4B0A-92C3-EC722B2C2DEC

P932

Q30497364-6881836F-17AB-49DE-BC72-2AD1C3AD9FBC

P356

P1433

P1476

Secretory phospholipase A2-IIa ...... biomarker for prostate cancer

@en

P2093

Barbara Burke

http://www.w3.org/2001/XMLSchema#string

Jiang Wang

http://www.w3.org/2001/XMLSchema#string

Kieran F Scott

http://www.w3.org/2001/XMLSchema#string

Krishnanath Gaitonde

http://www.w3.org/2001/XMLSchema#string

Leslie Oleksowicz

http://www.w3.org/2001/XMLSchema#string

Linda Levin

http://www.w3.org/2001/XMLSchema#string

Qihui Jim Zhai

http://www.w3.org/2001/XMLSchema#string

R Bruce Bracken

http://www.w3.org/2001/XMLSchema#string

Shan Lu

http://www.w3.org/2001/XMLSchema#string

Yin Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Mortality results from a randomized prostate-cancer screening trial

Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model

Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression

Transcriptional regulation of the rat type IIA phospholipase A2 gene by cAMP and interleukin-1beta in vascular smooth muscle cells: interplay of the CCAAT/enhancer binding protein (C/EBP), nuclear factor-kappaB and Ets transcription factors

Screening and prostate-cancer mortality in a randomized European study

The molecular mechanism of Vav3 oncogene on upregulation of androgen receptor activity in prostate cancer cells.

Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2

The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia.

Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer.

Prostaglandin E2 regulates tumor angiogenesis in prostate cancer.

P304

1948-1955

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CARCIN/BGQ188

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46255563

http://www.w3.org/2001/XMLSchema#string

P698

20837598

http://www.w3.org/2001/XMLSchema#string

P921

P932

2981059

http://www.w3.org/2001/XMLSchema#string